Last update Nov. 1, 2012

Quinagolide

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

It is a Prolactin-inhibitor and Dopamine-D2-receptor selective agonist drug used on patients with hyperprolactinemia who are not responsive to Bromocriptine. There has been released reports on prolonged breastfeeding by mothers affected of prolactinoma or hyperprolactinemia, some of them were receiving treatment with Prolactin-inhibiting drugs.

Alternatives

We do not have alternatives for Quinagolide.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Quinagolide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Quinagolide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Alta - Hig %
Molecular weight 396 daltons
Protein Binding 90 %
Tmax 2 hours
T1/2 17 hours

References

  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract

Total visits

3,886

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM